Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.

Functional loss of B-cell maturation antigen (BCMA) is a recognised mechanism of relapse after BCMA-directed chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory multiple myeloma. Targeting multiple tumour antigens simultaneously with a single CAR has the potential to mitigate antigen escape and prolong disease responses. Transmembrane activator and CAML interactor (TACI) and BCMA are both highly expressed on most myeloma cells and bind to the same natural ligan
Functional loss of B-cell maturation antigen (BCMA) is a recognised mechanism of relapse after BCMA-directed chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory multiple myeloma. Targeting multiple tumour antigens simultaneously with a single CAR has the potential to mitigate antigen escape and prolong disease responses. Transmembrane activator and CAML interactor (TACI) and BCMA are both highly expressed on most myeloma cells and bind to the same natural ligand-a proliferation-inducing ligand (APRIL). We designed TriPRIL, a CAR that uses an engineered trimeric form of APRIL, to target both BCMA and TACI. We aimed to establish the safety, tolerability, preliminary efficacy, and recommended phase 2 dose of autologous TriPRIL CAR T cells. In this first-in-human, open-label, dose-escalation and dose-expansion, phase 1 study, we evaluated TriPRIL in patients with relapsed or refractory multiple myeloma at Massachusetts General Hospital (Boston, MA, USA). Eligible patients had received at least three previous lines of therapy or had triple-class refractory disease. Previous CAR T-cell therapy and bispecific antibody therapy exposure were permitted. Patients received 3 days of lymphodepletion with intravenous cyclophosphamide (300 mg/m 2 ) and intravenous fludarabine (30 mg/m 2 ) daily on days -5, -4, and -3 before intravenous TriPRIL infusion on day 0. In the dose escalation phase, patients received 1·0 × 10 8 or 3·0 × 10 8 TriPRIL CAR T cells to establish the recommended phase 2 dose, which was further evaluated in the dose expansion phase. The primary endpoint was the incidence of study-related adverse events (graded according to Common Terminology Criteria for Adverse Events version 5) and dose-limiting toxicities in all patients who received an infusion of TriPRIL CAR T cells, until study completion at 24 months or progressive disease. The data cutoff date was March 24, 2026, when all infused patients had completed at least one assessment of disease response. This trial was registered at ClinicalTrials.gov (NCT05020444), has fully accrued, and is ongoing. Between Sept 17, 2021, and Jan 27, 2026, 16 patients were enrolled and underwent leukapheresis, with 15 patients subsequently receiving a TriPRIL cell infusion. Ten (67%) of 15 infused patients were female, five (33%)were male, and the median age was 69 years (IQR 65-75). Nine (60%) of 15 infused patients had previously received BCMA-directed CAR T-cell therapy, and four (27%) had previously received a BCMA-directed or GPRC5D-directed bispecific T-cell engager. Six patients were treated with 1·0 × 10 8 CAR T cells, and nine were treated with 3·0 × 10 8 CAR T cells; there were no dose-limiting toxicities at either dose. The most common adverse events were neutropenia (14 [93%] of 15 patients), nausea (12 [80%]), hypogammaglobulinaemia (eight [53%]), fatigue (seven [47%]), and fever (seven [47%]). Non-haematological adverse events grade 3 or worse occurred in five (33%) patients and all resolved. Cytokine release syndrome (grade 1 or 2 only) occurred in 13 (87%, 95% CI 60-98) infused patients. One (7%, 0-32) patient had grade 2 immune effector cell-associated neurotoxicity syndrome, and one (7%, 0-32) had grade 2 immune effector cell-associated haemophagocytic lymphohistiocytosis-like syndrome; both of these patients had received 3·0 × 10 8 CAR T cells, and both conditions resolved with corticosteroids. Infections occurred in six (40%, 16-68) infused patients, with a grade 3 infection in one patient (7%, 0-32). There were no treatment-related deaths. The recommended phase 2 dose of CAR T cells was set as 3·0 × 10 8 cells. TriPRIL showed a favourable safety profile and warrants further investigation in patients with relapsed or refractory multiple myeloma, including those previously treated with BCMA-directed CAR T-cell therapy. The study findings support further development of this dual-targeted, natural ligand-based CAR T-cell approach. Mass General Brigham and V Foundation.




